Chris Boshoff, MD, PhD, FMedSci’s Post

🎗️ On October 13th, in observance of Metastatic Breast Cancer Awareness Day, and throughout Breast Cancer Awareness Month, Prospection stands committed to increasing awareness and enhancing treatment outcomes for all forms of breast cancer. Prospection has collaborated with eight prominent pharmaceutical customers to leverage patient-centric intelligence to bring insight into the care journey for breast cancers patients. We’ve even developed algorithms specifically for understanding the 15-20% of breast cancer occurrences that are HER2-positive, a more aggressive–but treatable–subtype. 🟢 Reach out to us and discover how we can make a meaningful impact together. 👉  https://lnkd.in/gQ7jBnTS National Breast Cancer Foundation #BreastCancerAwarenessMonth #PatientCentricIntelligence #PinkOctober

Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer (RCC): The immunotherapy drug pembrolizumab (Keytruda) has rapidly become one of the most widely used cancer treatments. Based on updated results from a large clinical trial, the drug is now part of an important milestone in the treatment of kidney cancer—specifically, clear-cell renal cell carcinoma, the most common form of the disease: https://lnkd.in/enwtD-Ww

Recent Study: Prophylactic Use of Atorvastatin Protects Hearts Advances in breast cancer treatment have improved survival rates, but chemotherapy can harm the heart 💔. This study investigated using statins to prevent heart issues in breast cancer patients receiving anthracycline-based chemotherapy. 🎯 Objective: Evaluate statin's effect on anthracycline-induced cardiotoxicity in female breast cancer patients. 🧪 Study: Prospective, randomized, placebo-controlled trial with 110 patients. Half received atorvastatin, half received a placebo. 📊 Results: After 6 months, atorvastatin group had better heart function. Control group showed a significant drop in ejection fraction. 👉 Conclusion: Atorvastatin may protect breast cancer patients from chemotherapy-induced heart issues. https://lnkd.in/eYMthB5X #TeamCardioOncology 🏥💪

WEBINAR ALERT! 👉Join Dr. Tyler F. Stewart, a genitourinary malignancies expert from UC San Diego on June 11th, as he walks you through the journey of treating muscle invasive and advanced bladder cancer. From traditional chemotherapy to today's immunotherapy, discover the progress since BCAN began in 2005. Learn about personalized therapies, Antibody Drug Conjugates, and groundbreaking first-line combinations reshaping bladder cancer care. Understand the evolving landscape of bladder preservation. Click here to register: https://lnkd.in/gKtHvC3e

WEBINAR ALERT! 👉Join Dr. Tyler F. Stewart, a genitourinary malignancies expert from UC San Diego, as he walks you through the journey of treating muscle invasive and advanced bladder cancer. From traditional chemotherapy to today's immunotherapy, discover the progress since BCAN began in 2005. Learn about personalized therapies, Antibody Drug Conjugates, and groundbreaking first-line combinations reshaping bladder cancer care. Understand the evolving landscape of bladder preservation. Click here to register: https://lnkd.in/gKtHvC3e

At Johnson & Johnson Innovative Medicine, we are committed to leading where medicine is going – and nowhere is this more evident than in our rapidly expanding #LungCancer pipeline and portfolio.    We have submitted our third application to the U.S. FDA in four months for the treatment of lung cancer. This application focuses on our targeted therapy combination for the first-line treatment of patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).    This submission reinforces the potential of our targeted therapies to transform the standard of care for those with #NSCLC.   We will continue to pursue combination-based regimens that address the highest unmet needs in lung cancer. Learn more here: https://bit.ly/3GOkPtf   #MyCompany

Small cell lung cancer (SCLC) stands as a formidable and aggressive subtype of lung cancer, notorious for its rapid growth and propensity to metastasize early. Accounting for nearly 15% of all lung cancer cases, SCLC is characterized by its quick progression, often spreading to distant organs by the time of diagnosis. This cancer type’s aggressive nature requires clinical research to identify potential treatment modalities for patients with the disease. ASTRIDE is a Phase 3 clinical trial for the treatment of extensive stage SCLC. For Additional Information: https://lnkd.in/e42_UQ6P Fosun Pharma USA Inc. #lungcancer #SCLC The Balancing Act Lifetime Television#clincialtrials Payman Darouian Stan Lechpammer, MD, Ph.D. Brian Fiske George Eliades

PD1 and PDL1 inhibitors (in short, PDx) have changed cancer care since the approval of pembrolizumab for melanoma in 2014. The field has expanded since however the progress many patients are not responding to the treatment due to resistance. This overview provided by the Cancer Research Institute (CRI) describes the PDx trials and the emerging terms on the exclusion/inclusion of patients’ resistance. PDx continue to be the primary target of cancer immunotherapy. However, the occurrence of primary and acquired resistance to PDx is driving the development of more sophisticated combination therapy strategies, as well as the exploration of new IO targets in different immune cells. This study concludes that in 2022 the PDx clinical trial testing reduced across phase I to III, pointing to the heterogeneity of clinical strategy based on tumour type. Whereas PDx mAbs still dominate most of the field, PDx bispecific antibodies are gaining ground, and combinations of multiple agents are steadily displacing strategies such as dual combinations with chemotherapy or radiotherapy. Original Nature article link:  https://lnkd.in/gKTu9nai  #PDx #PD-L1 #Cancer #Trials #Immunotherapies #IO

In the phase 2 KEYLYNK-009 trial, investigators tested the efficacy and safety of maintenance therapy with pembrolizumab and olaparib vs pembrolizumab with chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who had clinical benefit from induction frontline pembrolizumab/platinum-based chemotherapy. There were no improvements in progression-free survival (PFS) or overall survival (OS) when combining pembrolizumab (Keytruda) with olaparib (Lynparza) compared with pembrolizumab plus chemotherapy in patients with locally recurrent or metastatic triple-negative breast cancer (TNBC), according to data from the phase 2 KEYLYNK-009 study (NCT04191135) presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Reference: https://lnkd.in/g2tQWhDu #pembrolizumab_olaparib #SABCS23 #tnbc #breastcancer

Learn about the new treatments available for triple-negative breast cancer! Advances like antibody-drug conjugates and PARP inhibitors, are changing how breast cancer is treated. Watch this video to see these innovative therapies and how they can benefit your treatment. This knowledge will help empower you in your journey towards breast cancer treatment. Share this information and help raise awareness! https://ow.ly/WXWm50SARB8